Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT to Launch New Cancer Focused CytoSure™ Array at CCMC Meeting

Published: Tuesday, July 30, 2013
Last Updated: Tuesday, July 30, 2013
Bookmark and Share
Reliable CCMC-standardised array for CNV and LOH detection in haematological malignancies and solid tumours.

Oxford Gene Technology (OGT) will launch its new CytoSure™ Consortium Cancer +SNP array (4x180k) at the Cancer Cytogenomics Microarray Consortium (CCMC) and Cytogenomics Array Group (CAGdb) combined meeting in Chicago on the 5th- 7th August, booth 4.

The new CytoSure™ Consortium Cancer +SNP array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb. Focusing on content recommended by the CCMC, an international organisation of clinical cytogeneticists, molecular cytogeneticists and molecular pathologists, this targeted array covers over 500 cancer genes and 130 cancer-associated genomic regions for haematological malignancies and solid tumours. The CCMC-approved standardised array design is intended to improve clinical research quality and promotes collaboration and communication between cancer cytogenomics laboratories.

The new array will be the latest addition to a range of OGT microarrays specifically designed for detecting CNV and LOH on a single array for cancer research. This includes the recently released CytoSure Cancer +SNP array (4x180k) covering 1500 cancer associated genes and the CytoSure Haematological Cancer + SNP array (8x60k) focused specifically on haematological cancers. Due to the unique design of OGT’s SNP probes, there are no changes to the standard aCGH protocol, no restriction digest is required and any reference sample can be used. This enables the use of matched samples which is a particular advantage in cancer research, allowing constitutional abnormalities to be filtered out. For effortless data analysis, OGT’s CytoSure Interpret Software is supplied with all CytoSure arrays and delivers reliable and user-friendly data analysis, providing rapid access to meaningful results.

James Clough, Executive Vice President Commercial at OGT, said: “The new CytoSure Consortium Cancer +SNP array is part of OGT’s commitment to advancing the field of cytogenetic cancer research. OGT’s collaborations in the design and development of our arrays with international organisations such as the CCMC who are leaders in cancer cytogenetics research, are testament to this. By providing reliable, high-quality CNV and SNP detection for haematological malignancies and solid cancers, these arrays are valuable tools for accurately and efficiently defining the genetic nature of cancers, advancing research into novel and improved therapeutics”.

Delegates of the CCMC / CAGdb meeting can find out more about OGT’s expertise in cancer cytogenetics by attending a talk by Ephrem Chin, Regional Sales manager at OGT, entitled ‘Oxford Gene Technology – Meeting laboratory needs’. The talk will be presented as part of the ‘Data quality and QC metrics’ workshop at 1 – 3pm on the 6th August and provides an opportunity for researchers to share in OGT’s extensive experience in high-throughput array processing and associated QC metrics and data analysis.

OGT representatives will also be available at booth 4 for the duration of the meeting.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Supports Earlier Lupus Diagnosis
Superior sensitivity and specificity compared to current laboratory tests.
Friday, May 10, 2013
OGT to Host Company Showcase at BioTrinity 2012
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.
Monday, April 23, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
OGT Releases New Whitepaper for Aiding Biomarker Discovery
The new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Tuesday, January 24, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT Named by Agilent as the First High-Throughput Microarray Certified Service Provider
Certificate confirms OGT as the world’s leading choice for large-scale outsourced microarray studies.
Wednesday, March 03, 2010
Scientific News
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
Microalgae Make a Splash in the UK Cosmeceutical Market
Scottish innovators have discovered an anti-viral and anti-inflammatory carbohydrate in microscopic algae (microalgae) which has huge potential to change the cosmetics market.
Mechanism of Tumor Suppressing Gene Uncovered
The most commonly mutated gene in cancer,p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
Useful Colon Cancer Biomarker Discovered
Biomarker is detectable with simple, inexpensive test.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Seeing Hope
Gene therapy/drug combo restores some vision in mice with optic nerve injury.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!